Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.00 USD
-0.24 (-2.60%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TVTX 9.00 -0.24(-2.60%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TVTX
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Other News for TVTX
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
Expert Ratings For Travere Therapeutics
Travere Therapeutics price target raised by $1 at Piper Sandler, here's why
Travere Therapeutics price target raised by $3 at Wedbush, here's why
Travere Therapeutics (TVTX) Gets a Hold from Piper Sandler